Percutaneous Skin Patch Market

Global Percutaneous Skin Patch Market Size, Share & Trends Analysis Report, By Type (Single-Layer Drug-in-Adhesive, Multi-Layer Drug-in-Adhesive, and Others), By Application (Neurologic Conditions, Pain Management, Nicotine Cessation, and Others), Forecast (2022-2028)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026225 | Category : Pharmaceuticals | Delivery Format: /

The global percutaneous skin patch market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The percutaneous patch is a method for drug delivery that works by sticking to the skin. Also known by the name as transdermal, these patches have medicinal ingredients on their surface which are absorbed through the skin and later channelized into the bloodstream. As intended, this patch improvises the drug delivery path through a predetermined dose of medication. The primary factor attributed to spur the market growth includes the growing regulatory approvals by various authorities as a positive measure to improve public health. For instance, in September 2021, Luye Pharma announced that it has received approval for Rivastigmine Multi-Day Transdermal Patch for treating mild to moderate dementia associated with Alzheimer's disease by the UK's Medicines and Healthcare Products Regulatory Agency. Such approvals are likely to boost the global percutaneous skin patch market.

Another key trend attributed to the rising demand for these skin patches includes the product innovation and enhancements that further raise patient adherence to their recommended therapeutics. For instance, in September 2021, ImQuest Biosciences has announced the launch of an antiretroviral (ARV) transdermal delivery patch. This patch was introduced as a substitute for oral medication for HIV patients. In addition to this, in December 2020, Agile Therapeutics Inc. announced the launch of Twirla (Levonorgestrel and Ethinyl Estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch, in the US. It is launched for women of reproductive potential who have a Body Mass Index (BMI) <30 kg/m2 for whom a combined hormonal contraceptive is appropriate to prevent pregnancy.

Market Coverage

  • The market number available for – 2021-2027
  • Base year- 2021
  • Forecast period- 2022-2028

Segment Covered- 

  • By Type 
  • By Application

Regions covered-

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape:  Teva Pharmaceutical Industries Ltd., Novartis International AG, and Mylan NV, among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Percutaneous Skin Patch Market Report by Segment

By Type

  • Single-Layer Drug-in-Adhesive
  • Multi-Layer Drug-in-Adhesive
  • Others

By Application

  • Neurologic Conditions 
  • Pain Management 
  • Nicotine Cessation
  • Others

Global Percutaneous Skin Patch Market Report by Region

North America       

  • US
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia-Pacific    

  • China
  • Japan
  • India
  • Rest of Asia-Pacific

Rest of the World

  • Latin America
  • Middle East and Africa